FLT3 and acute myeloid leukemia: The clinical efficacy of most of these inhibitors as monotherapy for AML was unimpressive, and their off-target inhibition also increased adverse events.106 Therefore, clinical studies on first-generation FLT3 inhibitors for AML monotherapy were discontinued except for midostaurin.